Advanced Gastric Adenocarcinoma Clinical Trials
22 clinical trials for Advanced Gastric Adenocarcinoma across international registries, including 5 currently recruiting participants. Compare status, phase, eligibility criteria and locations.
- Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial — RECRUITING · PHASE2
- mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma — RECRUITING · PHASE3
- Testing Ivonescimab in Combination With Chemotherapy in Advanced or Metastatic Gastric/Gastroesophageal Adenocarcinoma — RECRUITING · PHASE2
- Dual-target CLDN18.2/HER2 CAR-NK Cells for Advanced Gastric/GEJ Cancer — RECRUITING · PHASE1
- Total Neoadjuvant FLOT Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer — RECRUITING · PHASE2
- Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma — ACTIVE_NOT_RECRUITING · PHASE1
- Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric Adenocarcinoma — ACTIVE_NOT_RECRUITING · PHASE2
- PI3Kβ Selective Inhibitor With Paclitaxel, Advanced Gastric Adenocarcinoma — COMPLETED · PHASE1
- First-line Apatinib Combined With Tislelizumab and Chemotherapy for Advanced GC — COMPLETED · PHASE2
- Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors — COMPLETED · PHASE1
- A Study of the Advanced Adenocarcinoma of Stomach and Gastroesophageal Junction With Camrelizumab+SOX Control Camrelizumab+SOX+ Trastuzumab — OTHER · NA
- Study of AZD6094 (Volitinib) in Advanced Gastric Adenocarcinoma Patients With MET Amplification as a Third-line Treatment — COMPLETED · PHASE2
- Study of AZD1775 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring TP53 Mutation as a Second-line Chemotherapy — COMPLETED · PHASE2
- Phase Ib, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel, in Any Solid Cancer and Sequential Phase II, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel in Advanced Gastric Adenocarcinoma Patients With MET Amplification as a Second Line Treatment — COMPLETED · PHASE1
- Camrelizumab Combined With Albumin-bound Paclitaxel and S-1 in the Treatment of Advanced Gastric Cancer — OTHER · NA
- Prospectively Predict the Efficacy of Treatment of Gastrointestinal Tumors Based on Peripheral Multi-omics Liquid Biopsy — OTHER
- A Study to Evaluate the Safety and Efficacy of ly011 Cell Injection in the Treatment of Advanced Gastric Adenocarcinoma — OTHER · PHASE1
- Study of AZD6094 (Volitinib) in Combination With Docetaxel, in Advanced Gastric Adenocarcinoma Patients With MET Overexpression as a Second-line Treatment — COMPLETED · PHASE2
- PD-1 Antibody(SHR-1210) Plus Apatinib Combined With POF in Advanced Gastric Cancer — OTHER · NA
- Trial of AZD5363 Plus Paclitaxel /AZD2014 Plus Paclitaxel in Biomarker Negative (PIK3CA/MEK/RAS/TP53/MET) Gastric Adenocarcinoma Patients as Second-line Chemotherapy — TERMINATED · PHASE2
- Clinical Study of CAR-CLD18 T Cells in Patients With Advanced Gastric Adenocarcinoma and Pancreatic Adenocarcinoma — OTHER · NA
- Efficacy of HIPEC in the Treatment of Patients With Locally Advanced Gastric Cancer — OTHER · PHASE3
Refine this search